vTv Therapeutics (NASDAQ:VTVT) Stock Passes Below 50-Day Moving Average – Here’s What Happened

by · The Cerbat Gem

vTv Therapeutics Inc. (NASDAQ:VTVT – Get Free Report) shares passed below its 50-day moving average during trading on Friday . The stock has a 50-day moving average of $33.93 and traded as low as $33.21. vTv Therapeutics shares last traded at $35.08, with a volume of 94,154 shares traded.

Wall Street Analysts Forecast Growth

VTVT has been the subject of a number of research reports. Zacks Research cut shares of vTv Therapeutics from a “strong-buy” rating to a “hold” rating in a report on Thursday, June 11th. Weiss Ratings upgraded shares of vTv Therapeutics from a “sell (d-)” rating to a “sell (d+)” rating in a report on Monday, May 18th. BTIG Research reaffirmed a “buy” rating and issued a $49.00 target price on shares of vTv Therapeutics in a research report on Wednesday, March 11th. Evercore began coverage on shares of vTv Therapeutics in a report on Thursday, March 12th. They set an “outperform” rating and a $44.00 price target for the company. Finally, Wall Street Zen raised shares of vTv Therapeutics from a “hold” rating to a “buy” rating in a research report on Saturday, May 16th. Five research analysts have rated the stock with a Buy rating, one has issued a Hold rating and one has issued a Sell rating to the stock. According to MarketBeat.com, vTv Therapeutics has an average rating of “Moderate Buy” and an average target price of $53.00.

Read Our Latest Analysis on VTVT

vTv Therapeutics Stock Down 4.7%

The firm has a fifty day moving average price of $33.93 and a 200 day moving average price of $35.59. The company has a market cap of $138.22 million, a P/E ratio of -37.72 and a beta of 0.27.

vTv Therapeutics (NASDAQ:VTVT – Get Free Report) last announced its quarterly earnings data on Wednesday, May 13th. The biotechnology company reported $1.65 earnings per share for the quarter, topping the consensus estimate of $0.21 by $1.44. The firm had revenue of $36.84 million for the quarter, compared to the consensus estimate of $20.00 million. On average, sell-side analysts anticipate that vTv Therapeutics Inc. will post -2.19 earnings per share for the current year.

Institutional Trading of vTv Therapeutics

A number of large investors have recently added to or reduced their stakes in the company. 683 Capital Management LLC bought a new stake in vTv Therapeutics in the fourth quarter valued at approximately $731,000. Goldman Sachs Group Inc. bought a new position in vTv Therapeutics in the 4th quarter valued at about $221,000. Geode Capital Management LLC boosted its position in shares of vTv Therapeutics by 84.3% in the fourth quarter. Geode Capital Management LLC now owns 28,194 shares of the biotechnology company’s stock valued at $1,128,000 after acquiring an additional 12,896 shares during the period. Finally, Baker BROS. Advisors LP raised its holdings in vTv Therapeutics by 52.4% in the 3rd quarter. Baker BROS. Advisors LP now owns 148,314 shares of the biotechnology company’s stock valued at $3,463,000 after acquiring an additional 51,000 shares in the last quarter. Institutional investors and hedge funds own 17.51% of the company’s stock.

vTv Therapeutics Company Profile

(Get Free Report)

vTv Therapeutics, Inc is a clinical-stage biopharmaceutical company headquartered in Westport, Connecticut, focused on discovering and developing orally administered small-molecule therapies for chronic diseases. Employing its proprietary medicinal chemistry platform, the company seeks to generate novel compounds that modulate key disease pathways while optimizing safety and pharmacokinetic properties.

The company’s lead candidate, azeliragon (TTP488), is an oral inhibitor of the receptor for advanced glycation end products (RAGE) and has completed Phase II/III clinical evaluation in early-stage Alzheimer’s disease.

Featured Articles